RCA
TAK icon

Resonant Capital Advisors’s Takeda Pharmaceutical TAK Stock Holding History

Resonant Capital Advisors’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,245
Closed -$165K – 468
2025
Q3 		$165K Buy
+11,245
New +$167K 0.01% 432

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Resonant Capital Advisors's TAK Position: Q4 2025 in Review

Resonant Capital Advisors sold out of Takeda Pharmaceutical (TAK) in Q4 2025, closing a stake of 11,245 shares — an estimated $165K sold.

Resonant Capital Advisors first reported a position in TAK in Q3 2025 and held it in 1 quarter. The position peaked at $165K in Q3 2025. 349 funds tracked by Wall St. Rank hold TAK as of Q4 2025.

  • Resonant Capital Advisors reported no remaining Takeda Pharmaceutical position as of Q4 2025 after selling out during the quarter.
  • Resonant Capital Advisors sold 11,245 Takeda Pharmaceutical shares in Q4 2025, an estimated $165K.
  • Resonant Capital Advisors first reported a position in Takeda Pharmaceutical in Q3 2025 and held it in 1 quarter.
  • Resonant Capital Advisors's Takeda Pharmaceutical position peaked at $165K in Q3 2025.
  • 349 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q4 2025.

Based on Resonant Capital Advisors's 13F filing for Q4 2025, filed 29 Jan 2026.